No connection

Search Results

ARQT vs ICUI

ARQT
Arcutis Biotherapeutics, Inc.
BEARISH
Price
$22.75
Market Cap
$2.82B
Sector
Healthcare
AI Confidence
85%
ICUI
ICU Medical, Inc.
BEARISH
Price
$125.68
Market Cap
$3.14B
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
ARQT
--
ICUI
4189.33
Forward P/E
ARQT
17.79
ICUI
13.66
P/B Ratio
ARQT
14.81
ICUI
1.46
P/S Ratio
ARQT
7.5
ICUI
1.41
EV/EBITDA
ARQT
-359.13
ICUI
13.35

Profitability

Gross Margin
ARQT
90.24%
ICUI
36.84%
Operating Margin
ARQT
14.2%
ICUI
4.83%
Profit Margin
ARQT
-4.29%
ICUI
0.03%
ROE
ARQT
-9.3%
ICUI
0.04%
ROA
ARQT
-1.96%
ICUI
1.66%

Growth

Revenue Growth
ARQT
81.5%
ICUI
-14.1%
Earnings Growth
ARQT
--
ICUI
--

Financial Health

Debt/Equity
ARQT
0.6
ICUI
0.63
Current Ratio
ARQT
3.17
ICUI
2.39
Quick Ratio
ARQT
2.83
ICUI
0.99

Dividends

Dividend Yield
ARQT
--
ICUI
--
Payout Ratio
ARQT
0.0%
ICUI
0.0%

AI Verdict

ARQT BEARISH

ARQT's Piotroski F-Score of 1/9 indicates severe financial distress, with weak profitability, negative ROE and ROA, and no dividend, signaling poor operational health. Despite strong revenue growth of 81.5% YoY and a forward P/E of 17.79, the company remains unprofitable with a negative profit margin of -4.29% and no intrinsic value or Graham Number available. Insider selling totaling $5.12M in the last six months, including significant sales by the CEO and directors, reinforces bearish sentiment. The stock trades at a premium to its fundamentals, with a Price/Sales of 7.50 and Price/Book of 14.81, suggesting overvaluation relative to earnings and book value. Analysts' strong_buy consensus appears disconnected from the underlying financial deterioration.

Strengths
81.5% YoY revenue growth indicates strong market expansion and product demand
High gross margin of 90.24% reflects efficient production and pricing power
Strong current and quick ratios (3.17 and 2.83) suggest solid short-term liquidity
Risks
Piotroski F-Score of 1/9 signals extreme financial weakness and operational instability
Negative ROE (-9.30%) and ROA (-1.96%) indicate poor capital efficiency and unprofitability
Insider selling of $5.12M in 6 months, including CEO and directors, raises governance concerns
ICUI BEARISH

ICUI presents a stark contradiction between a strong balance sheet and a collapsing income statement. While the Piotroski F-Score of 8/9 indicates exceptional structural financial health, the company is suffering from a severe earnings crisis, evidenced by a P/E ratio of 4189.33 and a -131.5% Q/Q EPS growth. The massive disconnect between the current price ($125.68) and the Graham Number ($7.62) suggests the stock is trading at a significant premium based on future recovery hopes rather than current fundamentals. With revenue declining by 14.1% and insiders selling, the strong health score is currently insufficient to offset the operational deterioration.

Strengths
Strong Piotroski F-Score (8/9) indicating high structural health
Healthy Current Ratio (2.39) showing strong short-term liquidity
Manageable Debt/Equity ratio (0.63)
Risks
Severe earnings collapse with recent Q/Q EPS growth of -131.5%
Negative revenue growth (-14.10% YoY) indicating market share loss or demand drop
Extreme valuation disconnect (Current P/E 4189.33 vs Forward P/E 13.66)

Compare Another Pair

ARQT vs ICUI: Head-to-Head Comparison

This page compares Arcutis Biotherapeutics, Inc. (ARQT) and ICU Medical, Inc. (ICUI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile